Healthcare / Drug Manufacturers - Specialty & GenericLSE
$5.90
-0.05 (-0.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-9.2M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
N/A
•ROE
117.1%
↑Gross Margin
46.4%
↓Debt/Equity
-2.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+108.3%
FCF CAGR
—
FCF margin
-7.4%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $49.7M · net income $-17.7M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $49.7M | $49.7M | $32.2M | $13.1M | $5.5M |
| Net Income | $-17.7M | $-17.7M | $-27.2M | $-33.3M | $-49.8M |
| EBITDA | $-8.6M | $-8.6M | $-21.3M | $-30.3M | $-46.1M |
| EPS | — | — | -0.03 | -0.05 | -0.21 |
| Gross Margin | 46.4% | 46.4% | 46.4% | 30.8% | 44.7% |
| Operating Margin | -20.2% | -20.2% | -71.1% | -239.4% | -575.5% |
| Net Margin | -35.5% | -35.5% | -84.5% | -254.4% | -905.4% |
| Balance Sheet | |||||
| Debt/Equity | -2.00 | -2.00 | -20.02 | 1.35 | 1.12 |
| Current Ratio | 0.90 | 0.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-9.2M | $-40.1M | $-24.9M |
| Returns | |||||
| ROE | 117.1% | 117.1% | 2063.9% | -221.5% | -760.8% |
| Valuation | |||||
| P/B | — | — | — | 316.70 | 236.31 |
| Growth & Yield | |||||
| Revenue Growth | 54.4% | 54.4% | 145.9% | 138.0% | — |
| EPS Growth | — | — | 40.0% | 75.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+145.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
+145.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.